博、硕士研究生导师简介

林心建教授, 博士生导师、闽江****、海外高层次人才引进专家。 美国加州大学圣地亚哥分校（UCSD）医学院和癌症中心医学博士后（1997年-2000年），2017年回母校福建医科大学工作前为UCSD癌症中心研究员和肿瘤靶向药物研发课题组组长。美国癌症协会（American Association for Cancer Research）和临床肿瘤学会 (American Society of Clinical Oncology) 会员。长期从事肿瘤生物学、肿瘤药理学、药物基因组学等前沿领域的研究，主要研究方向包括肿瘤生长和转移的分子机制、抗癌药物耐药的分子机理、肿瘤靶向药物研发以及病原微生物致癌机制研究等。共发表SCI收录的学术论文54篇其中第一或通讯作者32篇, 累计影响因子263.039，单篇影响因子平均4.871，H-index = 26，共被SCI源期刊引用2529次 (截止日期2020年10月30日)。在国际上率先报道有错误倾向的DNA聚合酶蛋白的高表达与卵巢癌和结肠癌对铂类抗癌药物耐药有密切相关。首次发现铜的吸收载体CTR1介导顺铂的跨膜转运，以第一兼通讯作者发表该结果的论文（Lin et al. Molecular Pharmacology, 62: 1154-1159, 2002）受到国际同行的广泛重视，2011年被美国国家生物医学图书馆（National Biomedical Library）评为“同一研究领域被引论文Top one”的优秀论文。特邀为众多癌症研究相关的国际核心期刊评审论文。发明两项新颖的分别用于抗肿瘤药物筛选和肿瘤靶向毒素连接的分子技术并获美国发明专利 (US Patent No. 6,344,324；PCT/US2017/018116）。曾主持和参加多项分别由美国国立卫生部、医学研究基金会、美国癌症学会及制药公司资助的研究项目。国内在研课题包括国家自然科学基金面上项目、福建医科大学“高层次人才引进”专项启动基金、中央财政支持地方高校“创新团队建设”专项基金。
发表论文（第一或通讯作者）
1.Lin, X.and Howell, S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine- and paclitaxel-resistant variants after exposure to cisplatin. Molecular Pharmacology, 56: 390-395, 1999.
2.Lin, X., Kim, H.K., and Howell, S.B. The role of DNA mismatch repair in cisplatin mutagenicity. Journal of Inorganic Biochemistry, 77: 89-93, 1999.
3.Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., and Howell, S.B. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Molecular Pharmacology, 58: 1222-1229, 2000.
4.Lin, X., Gately, D.P., Hom, D., Mishima, M., Los, G., and Howell, S.B. Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter. International Journal of Cancer, 91: 555-562, 2001.
5.Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., and Howell, S.B. p53 modulates the effect of loss of DNA mismatch repair on sensitivity of colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Research, 61: 1508-1516, 2001.
6.Lin, X.*, Okuda, T., Holzer, A. and Howell, S.B. The copper transporter CTR1regulates cisplatin uptake in Saccharomyces cerevisiae. Molecular Pharmacology, 62: 1154-1159, 2002.(*Corresponding author)
7.Lin, X., Zhang, Q., Rice, J.R., Stewart, D.R., Nowotnik, D.P. and Howell, S.B.Improved targeting of platinum chemotherapeutics: the anti-tumor activity of the HPMA copolymer platinum agent AP5280 in murine tumor models. European Journal of Cancer, 40:291-297, 2004.
8.Okuda, T., Lin, X.*, and Howell, S.B. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Molecular Pharmacology, 67:1852-1860, 2005. (* Co-first author)
9.Lin, X., Trang, J., Okuda, T., and Howell, S.B. DNA polymerase zaccounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clinical Cancer Research, 12: 563-568, 2006.
10.Lin, X., Okuda, T., Trang, J., and Howell, S.B. hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology, 69: 1748-1754, 2006.
11.Lin, X.and Howell, S. B. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Molecular Cancer Therapeutics, 5: 1239-1247, 2006.
12.Yuan, X., Lin, X.*, Manorek, G., Kanatani, I., Cheung, L., Rosenblum, M.G. and Howell, S.B. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Molecular Cancer Therapeutics, 8: 1906-1915, 2009. (* Co-first author)
13.Yuan, X., Lin, X.*, Manorek, G., Howell, S.B. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer, 11: 61, 2011. (* Co-first author)
14.Kanatani, I., Lin, X.*, Yuan, X., Manorek, G., Shang, X, Cheung, L.H., Rosenblum, M.G., Howell, S.B. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemotherapy and Pharmacology, 86: 979-90, 2011. (* Co-first author)
15.Shang, X., Lin, X.*, Alvarez, E., Manorek, G., Howell, S.B. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia, 14: 974-85, 2012. (* Co-first author and co-corresponding author)
16.Shang, X., Lin, X.*, Manorek, G., Howell, S.B. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Molecular Pharmacology, 83: 85-94, 2013. (* Co-first author and co-corresponding author)
17.Lin, X.*, Shang, X., Manorek, G., Howell, S.B. Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PLOS ONE, 8(6): e67496, 2013.(*Co-first author and co-corresponding author)
18.Lin, X.*, Shang, X., Manorek, G., Fofana, M., and Howell, S.B. Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience, 1: 185-195, 2014. (*Co-first author and co-corresponding author)
19.Lan, J., Guo, P., Lin, Y., Mao, Q., Guo, L., Ge, J., Li, X., Jiang, J., Lin, X.*, Qiu, Y. Role of glycosyltransferase PomGnT1 in glioblastoma progression. Neuro-Oncology, 17: 211-222, 2015. (*Co-corresponding author)
20.Ding, Y., Xing, Z., Liu, B., Lin, X.*, Cao, D. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastases using susceptibility-weighted imaging. Brain and Behavior, 4: 841-849, 2014. (*Co-corresponding author)
21.Shang, X., Lin, X.*, Howell, S.B. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through ?-catenin. Cell Communication and Signaling, 12: 59-73, 2014. (*Co-first author and co-corresponding author)
22.Lin, X.,Shang, X, Howell, S.B., Integrin αV control of Cu homeostasis and cisplatin sensitivity. Cell Cycle, 13: 3317-3318, 2014.
23.Wang, Y., Ma, J., Shen, H., Wang, C., Sun, Y., Howell, S.B., Lin, X.*Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncology Reports, 32: 2150-2158, 2014. (*Corresponding author)
24.Ma, J., Yang, J., Wang, C., Zhang, N., Dong, Y., Wang, C., Wang, Y., and Lin, X.*Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 down-regulation. BioMed Research International, 2014:107671. doi: 10.1155/2014/107671. (*Corresponding author)
25.Chen, W.N., Liu, L.L., Jiao, B.Y., Lin, W.S., Lin, X.*, Lin X. Hepatitis B virus X protein increases the IL-1β-induced NF-κB activation via interaction with evolutionarily conserved signaling intermediate in Toll pathways (ECSIT). Virus Research, 195: 236-245, 2015. (*Co-corresponding author)
26.Wang, X., Zhang, C., Yan, X., Lan, B., Wang, J., Wei, C., Cao, X., Wang, R., Yao, J., Zhou, T., Zhou, M., Liu, Q., Jiang, B., Jiang, P., Kesari, S., Lin, X.*, Guo, F. A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria. Clinical Cancer Research, 22: 1445-1458, 2016. (*Co-corresponding author)
27.Ye, J., Huang, Q., Xu, J., Huang, J., Wang, J., Zhong, W., Chen, W., Lin, X.*, Lin, X. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. Journal of Cancer Research and Clinical Oncology, 144: 821-833, 2018. (*Co-corresponding author)
28.Li, Y., Yan, X.L., Shi, J.J., He, Y., Xu, J., Lin, L.Y., Chen, W.N., Lin, X.J.* and Lin, X.* Aberrantly expressed miR-188-5p promotes gastric cancer metastasis by activating Wnt/β-catenin signaling. BMC Cancer, 19:505, 2019.(*Co-corresponding author)
29.Chen, H.J., Zhang, Y., Ye, S.S., Wu, Q., Lin, Y.F., Sheng, K.Q., Chen, W.N., Lin, X.J.*, Lin, X. Chromatin remodeling factor BAF155 protects hepatitis B virus X protein (HBx) from ubiquitin-independent proteasomal degradation. Emerging Microbes and Infections, 8: 1393-1405, 2019. (*Co-corresponding author)
30.Guo, C.X., He, L., Yin, J.Y., Meng, X.G., Tan, W., Yang, G. P., Bo, T., Liu, J.P., Lin, X.J.*, Chen, X. Epidemiological and clinical features of pediatric COVID-19. BMC Medicine, 18(1):250, 2020. (*Co-corresponding author)
31.Dai, X.M., Zhang, Y.H., Lin, X.H., Huang, X.X., Zhang, Y., Xue, C.R., Chen, W.N., Ye, J.X., Lin, X.J.*, Lin, X. SIK2 functions as a tumor suppressor in gastric cancer by inhibition of autophagic degradation of protein phosphatases to repress AKT/GSK3β/β-catenin signaling. Molecular Oncology, 2020, in press (*Co-corresponding author)
32.Wu, S.X., Ye, S.S., Lin, X.H., Chen, Y., Zhang, Y., Jing, Z.T., Liu, W., Chen, W.N., Lin, X.J. *, Lin, X. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling. Cancer Letters, 2020, accepted. (*Co-corresponding author)